Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2). PACAP is now considered to be a potent neurotrophic and neuroprotective peptide. It plays an important role during the embryonic development of the nervous system. PACAP also protects neurons against various toxic insults in neuronal cultures of diverse origins. In vivo, PACAP shows neuroprotection in models of ischemic and traumatic brain injuries, and those of neurodegenerative diseases. The present review summarizes the findings on the neuroprotective potential of PACAP in models of neurodegenerative diseases, with special focus on in vitro and in vivo models of Parkinsons disease, Huntington chorea and Alzheimers disease. Based on these observations, both endogenous and exogenously administered PACAP or its novel analogs, fragments offer a novel therapeutic approach in the treatment of neurodegenerative diseases.
Keywords: PACAP, Parkinson's disease, Huntington chorea, Alzheimer's disease, adenylate, neurodegenerative, glucagon, vasoactive, splicing, phospholipase, ganglia, pathomechanism, nigrostiatal, dopamine, mesencephalon, catecholamine
Current Pharmaceutical Design
Title: Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Volume: 17 Issue: 10
Author(s): D. Reglodi, P. Kiss, A. Lubics and A. Tamas
Affiliation:
Keywords: PACAP, Parkinson's disease, Huntington chorea, Alzheimer's disease, adenylate, neurodegenerative, glucagon, vasoactive, splicing, phospholipase, ganglia, pathomechanism, nigrostiatal, dopamine, mesencephalon, catecholamine
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2). PACAP is now considered to be a potent neurotrophic and neuroprotective peptide. It plays an important role during the embryonic development of the nervous system. PACAP also protects neurons against various toxic insults in neuronal cultures of diverse origins. In vivo, PACAP shows neuroprotection in models of ischemic and traumatic brain injuries, and those of neurodegenerative diseases. The present review summarizes the findings on the neuroprotective potential of PACAP in models of neurodegenerative diseases, with special focus on in vitro and in vivo models of Parkinsons disease, Huntington chorea and Alzheimers disease. Based on these observations, both endogenous and exogenously administered PACAP or its novel analogs, fragments offer a novel therapeutic approach in the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Reglodi D., Kiss P., Lubics A. and Tamas A., Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589355
DOI https://dx.doi.org/10.2174/138161211795589355 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry CD93: Recent Advances and Implications in Disease
Current Drug Targets The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Symmetry Plane Detection in Brain Image Analysis: A Survey
Current Medical Imaging MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Aquaporin and Vascular Diseases
Current Neuropharmacology Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Natural Medicine:The Genus Angelica
Current Medicinal Chemistry EDITORIAL: Novel Signaling Pathway Based Therapeutics in Cancer and Other Diseases
Current Signal Transduction Therapy